Copyright
©2006 Baishideng Publishing Group Co.
World J Gastroenterol. Dec 7, 2006; 12(45): 7239-7249
Published online Dec 7, 2006. doi: 10.3748/wjg.v12.i45.7239
Published online Dec 7, 2006. doi: 10.3748/wjg.v12.i45.7239
Table 1 Recommended doses and schedules for HBV vaccine
| Vaccine | Patients | Dose(mcg) | Volume(mL) | Schedule(mo) |
| Engerix-B | < 11 yr | 10 | 0.5 | 0, 1, 6 |
| (GlaxoSmithKline, Research Triangle Park, NC) | 11-19 yr | 10 | 0.5 | 0, 1, 6 |
| > 20 yr | 20 | 1.0 | 0, 1, 6 | |
| Dialysis | 40 | 2.0 | 0, 1, 2, 6 | |
| Recombivax HB (Merk & Co. Inc., Whitehouse Station, NJ) | < 11 yr | 5 | 0.5 | 0, 1, 6 |
| 11-19 yr | 5 | 0.5 | 0, 1, 6 | |
| > 20 yr | 10 | 1.0 | 0, 1, 6 | |
| Predialysis/ dialysis | 40 | 1.0 | 0, 1, 6 |
- Citation: Lodato F, Mazzella G, Festi D, Azzaroli F, Colecchia A, Roda E. Hepatocellular carcinoma prevention: A worldwide emergence between the opulence of developed countries and the economic constraints of developing nations. World J Gastroenterol 2006; 12(45): 7239-7249
- URL: https://www.wjgnet.com/1007-9327/full/v12/i45/7239.htm
- DOI: https://dx.doi.org/10.3748/wjg.v12.i45.7239